Seelos Therapeutics to Participate in the Benchmark Healthcare Virtual Conference
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, will participate in the Benchmark Company Healthcare House Call Virtual Video 1x1 Investor Conference on June 15-16, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, will participate in the Benchmark Company Healthcare House Call Virtual Video 1x1 Investor Conference on June 15-16, 2020. Raj Mehra, Ph.D., Chairman and CEO, will host meetings through conference calls. Seelos focuses on developing therapies for central nervous system disorders and rare diseases, with a portfolio targeting conditions like Acute Suicidal Ideation in Major Depressive Disorder and Parkinson’s Disease.
Details
News Market Reaction – SEEL
The recorded move for SEEL in the trading session of this news was -3.09%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the Benchmark Company Healthcare House Call Virtual Video 1x1 Investor Conference, June 15-16, 2020.
Raj Mehra, Ph.D., Chairman and CEO, will host meetings via conference calls.
For additional information about the Benchmark Company Healthcare House Call Virtual Video 1x1 Investor Conference: https://benchmark-healthcare-house-call-virtual.events.issuerdirect.com/
About Seelos Therapeutics:
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), Sanfilippo syndrome, Parkinson’s Disease, other psychiatric and movement disorders plus orphan diseases.
For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.
Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.